500 Boylston Street, Boston, MA 02116 617-419-4700
Return to Results
RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07)
and non-smokers with cancer in the laboratory may help doctors learn more about changes that
occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more
about risk factors for lung cancer and may help the study of cancer in the future.
PURPOSE: This clinical trial is studying carcinogens in lung tissue from smokers (closed to
entry as of 7/15/07) and non-smokers with newly diagnosed stage I, stage II, or stage III
non-small cell lung cancer.
Ages:18 - 120
DISEASE CHARACTERISTICS: - Histologically confirmed non-small cell lung cancer - Stage I, II, IIIA, or IIIB (T4 or N3) disease - No malignant pleural effusion; if pleural fluid is present, 1 of the following criteria must be met: - Benign pleural fluid - Pleural fluid is due to prior thoracotomy - Pleural fluid is deemed too small to safely tap - No diagnosis by cytology alone - Newly diagnosed disease - Must have tumor blocks/slides available and must be willing to provide tissue samples - Prior smoking history meeting 1 of the following criteria: - Never smoker, defined as < 100 cigarettes in lifetime - Former smoker, defined as no smoking for ≥ 1 year - Current smoker, defined as all others (closed to accrual as of 7/15/07) - No pericardial effusions PATIENT CHARACTERISTICS: - No other prior malignancy except for 1 of the following: - Adequately treated basal cell or squamous cell skin cancer - In situ cervical cancer - Other cancer for which the patient has been disease free for five years PRIOR CONCURRENT THERAPY: - No prior chemotherapy or radiotherapy - Concurrent participation in therapeutic trials allowed
Sponsor: Southwest Oncology Group
Trial ID: NCT00450281
Not Accepting Healthy Volunteers